Clinical Validation of AI-Powered PD-L1 Tumor Proportion Score Interpretation for Predicting Immune Checkpoint Inhibitor Response in NSCLC

Information Science, Artificial Intelligence, Medicine, Medical Laboratory Science, Oncology,
Artificial Intelligence   PD-L1   Tumor Proportion Score   Non-Small Cell Lung Cancer   Immune Checkpoint Inhibitors   Clinical Validation  

Clinical Validation of AI-based Interpretation of PD-L1 Tumor Proportion Score in Predicting Response to Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer In the field of tumor treatment and diagnosis, the assessment of PD-L1 (Programmed Death-Ligand 1) Tumor Proportion Score (TPS) is a critical task, especially in predicting the response ...

Genomic Profiling of Rare Undifferentiated Sarcomatoid Subtypes of Pancreatic Carcinomas: In Search of Therapeutic Targets

Medicine, Medical Laboratory Science, Oncology, Life Sciences, Biochemistry, Immunology,
Undifferentiated Sarcomatoid Carcinoma   Pancreatic Cancer   Genomic Profiling   Therapeutic Targets   Immune Checkpoint Inhibitors  

Genomic Characteristics of a Rare Pancreatic Cancer Undifferentiated Sarcomatoid Carcinoma Subtype Academic Background Pancreatic Ductal Adenocarcinoma (PDAC) is one of the deadliest cancers, characterized by early invasion and metastasis. Undifferentiated Sarcomatoid Carcinoma (USC) is a particularly aggressive but rare subtype of PDAC, accounting...

Epithelial−Mesenchymal Transition Induced by Tumor Cell-Intrinsic PD-L1 Signaling Predicts a Poor Response to Immune Checkpoint Inhibitors in PD-L1-High Lung Cancer

Medicine, Rheumatology and Immunology, Respiratory System, Oncology, Life Sciences, Cell Biology, Biochemistry, Immunology,
PD-L1   Epithelial-Mesenchymal Transition   Non-Small-Cell Lung Cancer   Immune Checkpoint Inhibitors   Biomarkers   Tumor Progression  

Tumor Cell-Intrinsic PD-L1 Signaling Induces Epithelial-Mesenchymal Transition (EMT) Predicting Poor Response to Immune Checkpoint Inhibitors in PD-L1 High-Expressing Lung Cancer Research Background and Motivation In cancer immunotherapy, Programmed Death Ligand-1 (PD-L1) inhibits immune responses by binding to Programmed Death-1 (PD-1) receptors o...

Study of Lifileucel, an Autologous Tumor-Infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non–Small Cell Lung Cancer Resistant to Immune Checkpoint Inhibitors

Study of Lifileucel, an Autologous Tumor-Infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non–Small Cell Lung Cancer Resistant to Immune Checkpoint Inhibitors

Medicine, Respiratory System, Oncology, Life Sciences, Immunology,
Autologous Tumor-Infiltrating Lymphocyte   Advanced Non–Small Cell Lung Cancer   Immune Checkpoint Inhibitors   Monotherapy   Treatment Efficacy  

Application of Lifileucel in Advanced Non-Small Cell Lung Cancer Patients Resistant to Immune Checkpoint Inhibitors This article, authored by Adam J. Schoenfeld and numerous other top scholars, was published in the 2024 edition of Cancer Discovery. The study is based on a multi-center phase II clinical trial aiming to evaluate the efficacy and safe...